ACP-211 vs ALA-3000

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ACP-211

Developed by Acadia Pharmaceuticals

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07284667 (registry estimate)

No aligned efficacy figure on record for this race.

ALA-3000

Developed by Alar Pharmaceuticals

Phase 1 in Major Depressive Disordersmall molecule
Partial signal

NCT06965569 · Phase 1 · completed

This randomized, double-blind, placebo-controlled multiple-dose study gave subcutaneous ALA-3000 or placebo, with a standard oral antidepressant, to patients with treatment-resistant depression. All of its primary measures were safety and tolerability measures, which have no formal efficacy test, so there is no met or missed result. The company reports that side effects were mild to moderate and that no dissociation, sedation or psychosis-like symptoms were seen. Effects on depression scores were exploratory. The figures come from the company's press release.

Reported efficacy

Incidence of treatment-related adverse events (AEs) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal orthostatic blood pressure (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal heart rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal blood oxygen saturation (pulse oximetry) (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal respiratory rate (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal body temperature (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal 12-lead electrocardiogram (ECG) parameters (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal hematologic findings (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal serum chemistry test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine test result (Baseline (prior to dosing) through the End of Study (Day 36)/Early termination or Follow up visit); Incidence of abnormal urine cytologic findings (Baseline (prior to dosing) and the End of Study (Day 36) visit); Incidence and severity of dissociative symptoms assessed by Clinician Administered Dissociative States Scale (CADSS) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of treatment-emergent sedation assessed by Modified Observer's Assessment of Alertness/ Sedation (MOAA/S) (Baseline (prior to dosing) through the End of Study (Day 36)); Incidence and severity of potential withdrawal symptoms assessed by Physician Withdrawal Checklist; 20-item (PWC-20) (Two weeks after last investigational product administration and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of suicide ideation assessed by Columbia Suicide Severity Rating Scale (C-SSRS) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination or Follow up visit); Incidence and severity of four-item positive symptom subscale of the Brief Psychiatric Rating Scale (BPRS+) (Baseline (prior to dosing) and through the End of Study (Day 36)/Early termination); Injection site tolerability based on injection site grading scale (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site pain visual analog scale (VAS) (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit); Injection site tolerability based on injection site evaluation for potential reactions and evidence of removal (At the time of injection and through the End of Study (Day 36)/Early termination or Follow up visit): Primary, safety and tolerability (no formal efficacy test): treatment-related adverse events were mild to moderate in severity, and no dissociation, sedation or psychosis-like symptoms were observed. (not_applicable)

Result source: NCT06965569

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACP-211ALA-3000
MADRS, change (acute)—Not reported—Not reported
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ACP-211
—Not reported
ALA-3000
—Not reported

CGI-S, change (acute)

ACP-211
—Not reported
ALA-3000
—Not reported

MADRS response

ACP-211
—Not reported
ALA-3000
—Not reported

MADRS remission

ACP-211
—Not reported
ALA-3000
—Not reported

Relapse (% of patients)

ACP-211
—Not reported
ALA-3000
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ACP-211: no structured comparison results are available for Major Depressive Disorder.

ALA-3000: no structured comparison results are available for Major Depressive Disorder.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · ALA-3000's landscape